62nd ASH Annual Meeting and Exposition: 904. Outcomes Research—Non-Malignant Conditions: Bleeding, Immune Thrombocytopenia, and Other Hematologic Disorders

Oral and Poster Abstracts
Oral

Bleeding Disorders, Hemophilia, Adult, antibodies, autoimmune disorders, Biological, Diseases, Bleeding and Clotting, Non-Biological, Elderly, platelets, Therapies, ITP, Pediatric, Biological Processes, MPN, Immune Disorders, Young Adult, Cell Lineage, Study Population, Clinically relevant, Myeloid Malignancies, Quality Improvement , immune mechanism, VWD

Moderators:

Susan E Creary, MD, Nationwide Children's Hospital and Rachael F. Grace, MD, Children's Hospital Boston

Disclosures:

Grace: Agios: Research Funding; Dova: Membership on an entity's Board of Directors or advisory committees; Novartis: Research Funding; Pfizer: Research Funding.

9:30 AM

147

Effect of Moderate and Severe Hemophilia a on Daily Life in Children and Their Caregivers: A CHESS Paediatrics Study Analysis

Kate Khair, PhD^1,2^*, Francis Nissen³^*, Mariabeth Silkey³^*, Tom Burke²^*, Aijing Shang, MD, PhD³^*, Martynas Aizenas³^*, Oliver Meier³^*, Jamie O'Hara, MSc^2,4^* and Declan Noone, MSc²^*

¹Haemnet, London, United Kingdom
²HCD Economics, Daresbury, United Kingdom
³F. Hoffmann-La Roche Ltd, Basel, Switzerland
⁴University of Chester, Chester, United Kingdom

9:45 AM

148

Validation Study of the Heavy Menstrual Bleeding Questionnaire in Adolescents

Meghan Pike, MD¹, Ashley Chopek, MD²^*, Nancy Young³^*, Koyo Usuba³^*, Mark J. Belletrutti, MD, MSc⁴, Robyn McLaughlin⁵^*, Nancy Van Eyk⁵^*, Amanda Bouchard⁵^*, Kristen Matteson⁶^* and Victoria E. Price, MBChB, MD⁵^*

¹IWK Health Centre, Bedford, NS, Canada
²CancerCare Manitoba, Winnipeg, MB, CAN
³Hospital for Sick Kids, Toronto, Canada
⁴Pediatrics, University of Alberta, Edmonton, AB, Canada
⁵IWK Health Centre, Halifax, NS, Canada
⁶Warren Alpert Medical School of Brown University, Providence

10:00 AM

149

Extensive Variability in Platelet Count, Bleeding, and Quality of Life Outcome Measures in Adult and Pediatric Immune Thrombocytopenia: An Appraisal from a Critical Review of the Literature

Hanny Al-Samkari, MD^1,2, Alexandria Cronin, MLIS³^*, Donald M. Arnold, MD, MSc⁴, Francesco Rodeghiero, MD⁵ and Rachael F. Grace, MD^1,6,7

¹Harvard Medical School, Boston, MA
²Division of Hematology, Massachusetts General Hospital, Boston, MA
³Boston Children's Hospital, Boston, MA
⁴Michael G. DeGroote School of Medicine, Department of Medicine, McMaster University, Hamilton, ON, Canada
⁵Department of Haematology, Hematology Project Foundation, S. Bortolo Hospital, Vicenza, Vicenza, Italy
⁶Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Children's Hospital Boston, Boston, MA
⁷Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, MA

10:15 AM

150

Decision Aid to Support Shared Decision Making in Pediatric Refractory Immune Thrombocytopenia

Manpreet K Kochhar, MD¹, Stephanie Grilo, PhD²^*, Laura Robbins, DSW³^*, Marina Catallozzi, MD²^* and Cindy Neunert, MD²

¹The Warren Alpert Medical School of Brown University, Providence, RI
²Columbia University, New York, NY
³Hospital for Special Surgery, New York, NY

10:30 AM

151

Longitudinal Analysis of Anemia Severity, Treatment and Healthcare Resource Utilization Among Patients with Primary Cold Agglutinin Disease in a Large US Database

Amanda Wilson¹^*, Florence Joly²^*, Gandarvaka Miles³^*, Kammy Kuang³^* and Huy P Pham, MD, MPH⁴^*

¹Sanofi, Cambridge, MA
²Sanofi, Chilly-Mazarin, France
³Aetion, Inc., New York, NY
⁴Department of Pathology, University of Southern California, Los Angeles, CA

10:45 AM

152

To Treat or Not to Treat? Understanding Treatment Patterns in Patients with Lower-Risk Myelofibrosis at the Time of Enrollment in the MOST Study

Rami S. Komrokji, MD¹, Brady L. Stein, MD, MHSc²^*, Robyn M. Scherber, MD³, Patricia Kalafut, PhD³^*, Haobo Ren, PhD³^* and Srdan Verstovsek, MD, PhD⁴

¹H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
²Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL
³Incyte Corporation, Wilmington, DE
⁴Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

904.O3.6 904. Outcomes Research—Non-Malignant Conditions: Bleeding, Immune Thrombocytopenia, and Other Hematologic Disorders